Search Result
Results for "
gastric acid secretion and
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
11
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P1139
-
|
PCFWKTCK
|
GHSR
|
Metabolic Disease
|
|
Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .
|
-
-
- HY-19010A
-
|
SKF 94482 hydrochloride
|
Histamine Receptor
|
Neurological Disease
|
|
BMY-25368 hydrochloride is a histamine H2 receptor antagonist that acts as a gastric acid secretion inhibitor. BMY-25368 hydrochloride competitively antagonizes gastric secretion stimulated by histamine and also antagonizes gastric secretion stimulated by Pentagastrin (HY-A0261), Bethanechol (HY-B0406), and food .
|
-
-
- HY-19010
-
|
SKF 94482
|
Histamine Receptor
|
Neurological Disease
|
|
BMY-25368 (SKF 94482) is a histamine H2 receptor antagonist that acts as a gastric acid secretion inhibitor. BMY-25368 competitively antagonizes gastric secretion stimulated by histamine and also antagonizes gastric secretion stimulated by Pentagastrin (HY-A0261), Bethanechol (HY-B0406), and food .
|
-
-
- HY-P3577
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .
|
-
![[Tyr0] Gastric Inhibitory Peptide (23-42), human](//file.medchemexpress.eu/product_pic/hy-p3577.gif)
-
- HY-106550
-
|
RS 84135
|
Prostaglandin Receptor
|
Endocrinology
|
|
Enprostil (RS 84135) is a prostaglandin E2 derivative. Enprostil can inhibit amogastrin-stimulated gastric acid secretion, as well as reducing the secretion of pepsin. Enprostil can also serve as an antiulcer agent, used for research of duodenal or gastric ulcers .
|
-
-
- HY-169833
-
|
|
Histamine Receptor
|
Inflammation/Immunology
|
|
BL 6341A is an antagonist for histamine H2 receptor with Ki of 3.5-4.4 nM, that inhibits histamine-induced acid secretion and cAMP formation. BL 6341A can be used in research of gastric acid secretion related diseases, such as gastric ulcer or gastroesophageal reflux .
|
-
-
- HY-100284
-
-
-
- HY-117358
-
|
|
Others
|
Inflammation/Immunology
|
|
KW-5805 is an anti-ulcer agent that promotes the biosynthesis, storage and secretion of gastric mucus, improves gastric mucosal hemodynamics, and inhibits the decrease in gastric mucosal blood volume and mucosal oxygenation caused by steroid shock .
|
-
-
- HY-167698
-
-
-
- HY-118367
-
-
-
- HY-109023
-
|
|
Proton Pump
Na+/K+ ATPase
|
Others
|
|
Azeloprazole is a compound used to inhibit acid-related diseases. It is a proton pump inhibitor that inhibits H?,K?-ATPase in pig gastric vesicles. It can effectively inhibit gastric acid secretion in the dog's gastric fistula model. The effect is long-lasting and superior to esomeprazole.
|
-
-
- HY-U00360
-
|
(Rac)-Netazepide; (Rac)-YF 476; (Rac)-YM-220
|
Cholecystokinin Receptor
|
Metabolic Disease
|
|
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.
|
-
-
- HY-19580
-
|
CM 57755A
|
Histamine Receptor
|
Endocrinology
|
Ramisotidine is a histamine H2 receptor antagonist that can inhibit gastric acid secretion stimulated by pentagastrin .
|
-
-
- HY-105094
-
|
NC 1300O3
|
Na+/K+ ATPase
|
Inflammation/Immunology
|
|
Leminoprazole (NC 1300O3) is an inhibitor for acid pump, H + K +-ATPase,. Leminoprazole stimulates the secretion and synthesis of gastric mucus, attenuates gastric ulcers. Leminoprazole is orally active .
|
-
-
- HY-103261
-
|
|
Proton Pump
|
Endocrinology
|
|
SCH28080 is a reversible, K +-competitive inhibitor of the gastric H,K-ATPase, with a Ki of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity .
|
-
-
- HY-15541
-
|
CP-57361
|
Histamine Receptor
|
Endocrinology
|
|
Zaltidine dihydrochloride (CP-5736 dihydrochloride) is a highly specific H2 receptor antagonist with antisecretion activity. Zaltidine dihydrochloride reduces the stimulant effect of histamine on gastric acid secretion by binding to histamine H2 receptors on gastric parietal cells, thus reducing gastric acid production. Zaltidine dihydrochloride can be used in the study of gastric acid-related diseases such as duodenal ulcers .
|
-
-
- HY-15541A
-
|
CP-5736 dihydrochloride
|
Histamine Receptor
|
Endocrinology
|
|
Zaltidine (CP-5736) dihydrochloride is a highly specific H2 receptor antagonist with antisecretion activity. Zaltidine dihydrochloride reduces the stimulant effect of histamine on gastric acid secretion by binding to histamine H2 receptors on gastric parietal cells, thus reducing gastric acid production. Zaltidine dihydrochloride can be used in the study of gastric acid-related diseases such as duodenal ulcers .
|
-
-
- HY-P2416
-
-
-
- HY-P1784
-
|
|
Secretin Receptor
|
Endocrinology
|
|
Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway .
|
-
-
- HY-125556
-
|
Cholecystokinin tetrapeptide; CCK-4
|
Cholecystokinin Receptor
|
Metabolic Disease
|
|
Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion . Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist . Gastric mucosal protection .
|
-
-
- HY-P0253
-
-
-
- HY-P1097
-
-
-
- HY-116777A
-
|
SKF 92676 hydrochloride
|
Histamine Receptor
|
Others
|
|
Impromidine hydrochloride is a potent agonist for histamine H2 receptor. Impromidine hydrochloride induces gastric mucosal blood flow and acid secretion .
|
-
-
- HY-129415
-
|
Hexaprazole
|
Others
|
Others
|
|
Esaprazole (Hexaprazole) is an antiulcer agent that has the effect of promoting the healing of peptic ulcer. Esaprazole can inhibit the secretion of gastric acid and pepsin .
|
-
-
- HY-171037
-
|
PGBx
|
Mitochondrial Metabolism
|
Neurological Disease
|
|
Prostaglandin Bx (PGBx) is an oligomer of PGB1 and 15-keto-PGB, which exhibits mitochondrial protective efficacy. Prostaglandin Bx promotes the neurological recovery in rabbits ischemic spinal cord injury model, and maintains the integrity of the gastric mucosa through inhibition of gastric acid secretion in rat gastric ulcer model .
|
-
-
- HY-P0253A
-
|
|
Neurotensin Receptor
|
Metabolic Disease
|
|
Xenopsin TFA, a neurotensin-like octapeptide from Xenopus laevis skin . Xenopsin TFA is an inhibitor of Tetragastrin stimulated gastric acid secretion .
|
-
-
- HY-116777
-
|
SKF 92676
|
Histamine Receptor
|
Others
|
|
Impromidine (SKF 92676) is a potent agonist for histamine H2 receptor. Impromidine induces gastric mucosal blood flow and acid secretion .
|
-
-
- HY-B0377
-
-
-
- HY-B1475
-
|
Octatropine bromide
|
mAChR
|
Neurological Disease
Metabolic Disease
|
|
Anisotropine (Octatropine) bromide is an orally active anticholinergic muscarinic antagonist. Anisotropine bromide can inhibit gastric acid secretion and is used as an adjunct to peptic ulcers .
|
-
-
- HY-117216
-
-
-
- HY-124235
-
|
|
Na+/K+ ATPase
|
Others
|
|
SK&F 97574 hydrochloride is a reversible inhibitor for H+/K+ ATPase, that reduces gastric acid secretion and promotes the healing of acid-related upper gastrointestinal ulcers .
|
-
-
- HY-169223
-
|
|
Endogenous Metabolite
|
Endocrinology
|
|
Roxatidine hydrochloride is an anti-ulcer compound with the activity of inhibiting gastric acid secretion. Roxatidine hydrochloride effectively inhibits duodenal and gastric ulcers and reduces ulcer pain. Roxatidine hydrochloride has a better safety profile than other similar compounds due to the lower dose required for effective inhibition .
|
-
-
- HY-B1478
-
|
|
Histamine Receptor
NO Synthase
|
Endocrinology
|
|
Dimaprit dihydrochloride is a selective histamine H2 receptor agonist, it also inhibits nNOS with an IC50 of 49 μM. Dimaprit dihydrochloride can stimulate gastric acid secretion .
|
-
-
- HY-17507E
-
|
|
Proton Pump
Bacterial
|
Infection
|
|
S-Pantoprazole (sodium trihydrate) is related to Pantoprazole (HY-17507) that plays an important roles in gastric acid secretion disorder-related diseases, or as proton pump inhibitor .
|
-
-
- HY-117216A
-
-
-
- HY-117216B
-
-
-
- HY-P0276
-
|
gastric Inhibitory Peptide (GIP), human
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
|
-
-
- HY-153219A
-
|
|
Potassium Channel
|
Endocrinology
|
|
P-CAB agent 2 is a potent and orally active potassium-competitive acid blocker and a gastric acid secretion inhibitor. P-CAB agent 2 inhibits H +/K +-ATPase activity with an IC50 value of <100 nM. P-CAB agent 2 inhibits the hERG potassium channel with an IC50 value of 18.69 M. P-CAB agent 2 shows no acute toxicity and inhibits histamine (HY-B1204)-induced gastric acid secretion .
|
-
-
- HY-153219
-
|
|
Potassium Channel
|
Endocrinology
|
|
P-CAB agent 2 hydrochloride is a potent and orally active potassium-competitive acid blocker and a gastric acid secretion inhibitor. P-CAB agent 2 hydrochloride inhibits H +/K +-ATPase activity with an IC50 value of <100 nM. P-CAB agent 2 hydrochloride inhibits the hERG potassium channel with an IC50 value of 18.69 M. P-CAB agent 2 hydrochloride shows no acute toxicity and inhibits histamine (HY-B1204)-induced gastric acid secretion .
|
-
-
- HY-W003467
-
|
|
Proton Pump
Bacterial
|
Infection
Inflammation/Immunology
|
|
Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H +/K +)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .
|
-
-
- HY-B1789A
-
|
|
mAChR
|
Neurological Disease
|
|
Telenzepine dihydrochloride is a selective and orally active muscarinic M1 receptor antagonist with a Ki of 0.94 nM. Telenzepine dihydrochloride inhibits gastric acid secretion and has antiulcer effects .
|
-
-
- HY-P0276A
-
|
gastric Inhibitory Peptide (GIP), human TFA
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
|
-
-
- HY-B1557
-
|
Ametazole
|
Histamine Receptor
|
Metabolic Disease
|
|
Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .
|
-
-
- HY-116208
-
|
KU-1257
|
Histamine Receptor
|
Inflammation/Immunology
|
|
Dalcotidine (KU-1257) is an orally active and competitive histamine H2 receptor antagonist. Dalcotidine promotes the healing of chronic ulcers and inhibits gastric acid secretion .
|
-
-
- HY-129579
-
|
|
Histamine Receptor
|
Others
|
|
Linadryl is a compound with antihistamine and other effects. It has a variable effect on gastric acid secretion after oral administration, and its effect is about half that of Diphenhydramine (HY-B0303).
|
-
-
- HY-B1557A
-
|
Ametazole dihydrochloride
|
Histamine Receptor
|
Metabolic Disease
|
|
Betazole (Ametazole) dihydrochloride, a pyrazole analogue of histamine, is an orally active H2 receptor agonist. Betazole dihydrochloride induces gastric acid secretion, and causes an immediate and significant increase in common bile duct pressure. Betazole dihydrochloride has been used as a diagnostic agent known as histalog, for investigating gastric acid secretory capacity .
|
-
-
- HY-121450
-
|
Loxtidine; AH-234844
|
Histamine Receptor
|
Cancer
|
|
Lavoltidine (Loxtidine) is an an orally active, irreversible and highly potent histamine H2-receptor antagonist. Lavoltidine strongly inhibits gastric acid secretion and also induces hypergastrinemia .
|
-
-
- HY-103281
-
|
|
Bombesin Receptor
|
Metabolic Disease
|
|
Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .
|
-
-
- HY-125610
-
-
-
- HY-123662
-
|
|
Proton Pump
|
Others
|
|
AGN-201904Z is a compound that inhibits gastric acid secretion and is a new type of proton pump inhibitor that can produce more significant and lasting acid suppression effects than esomeprazole.
|
-
- HY-B0305A
-
|
HOE 760
|
Histamine Receptor
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Roxatidine Acetate Hydrochloride is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine Acetate Hydrochloride has antisecretory potency against gastric acid secretion. Roxatidine Acetate Hydrochloride can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine Acetate Hydrochloride has antitumor activity .
|
-
- HY-B0305
-
|
|
Histamine Receptor
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Roxatidine acetate is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine acetate has antisecretory potency against gastric acid secretion. Roxatidine acetate can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine acetate has antitumor activity .
|
-
- HY-W008614
-
|
AG-1813
|
Drug Metabolite
Proton Pump
|
Metabolic Disease
|
|
Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
|
-
- HY-114966
-
-
- HY-P1806A
-
-
- HY-W009934
-
|
α-Phenyl-2-pyridineacetonitrile
|
Drug Metabolite
|
Endocrinology
|
|
2-Phenyl-2-(2-pyridyl)acetonitrile is the major metabolite of SC 15396 metabolized by the supernatant fraction of rat liver homogenate. SC 15396 is an antigastrin that inhibits gastric secretion .
|
-
- HY-129923
-
|
|
Cytochrome P450
|
Neurological Disease
|
|
(R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19 .
|
-
- HY-103276
-
-
- HY-17623D
-
|
CJ-12420 Benzoate; RQ-00000004 Benzoate
|
Proton Pump
|
Metabolic Disease
|
|
Tegoprazan Benzoate is the benzoate form of Tegoprazan (HY-17623). Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
|
-
- HY-W003467R
-
|
|
Proton Pump
Bacterial
|
Infection
Inflammation/Immunology
|
|
Rabeprazole Sulfide (Standard) is the analytical standard of Rabeprazole Sulfide. This product is intended for research and analytical applications. Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H +/K +)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .
|
-
- HY-B1557R
-
|
|
Histamine Receptor
|
Metabolic Disease
|
|
Betazole (Standard) is the analytical standard of Betazole. This product is intended for research and analytical applications. Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .
|
-
- HY-17623
-
|
CJ-12420; RQ-00000004
|
Proton Pump
Potassium Channel
Na+/K+ ATPase
|
Inflammation/Immunology
|
Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H +/K +-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H +/K +-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
|
-
- HY-B0377R
-
|
|
Histamine Receptor
|
Metabolic Disease
Endocrinology
Cancer
|
|
Famotidine (Standard) is the analytical standard of Famotidine. This product is intended for research and analytical applications. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
|
-
- HY-17623R
-
|
|
Proton Pump
|
Metabolic Disease
|
|
Tegoprazan (Standard) is the analytical standard of Tegoprazan. This product is intended for research and analytical applications. Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
|
-
- HY-B0377G
-
|
MK-208 (GMP)
|
Histamine Receptor
|
Inflammation/Immunology
Cancer
|
|
Famotidine GMP (MK-208 GMP) is Famotidine (HY-B0377) produced in GMP guideline. Famotidine GMP is a competitive histamine H2-receptor antagonist, inhibits gastric secretion, activates the gastric mucosal defensive mechanisms. Famotidine GMP ameliorates peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) in rats model .
|
-
- HY-17021B
-
|
(S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt
|
Proton Pump
Bacterial
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .
|
-
- HY-P1070
-
|
DAP amide, human
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .
|
-
- HY-W011245
-
|
|
Drug Metabolite
|
Metabolic Disease
|
|
Ranitidine S-oxide is the metabolite of Ranitidine (HY-B0693). Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion .
|
-
- HY-17021
-
|
(S)-Omeprazole; (-)-Omeprazole
|
Proton Pump
Bacterial
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
|
-
- HY-W002039
-
|
DL-β-Phenylalanine
|
Biochemical Assay Reagents
|
Endocrinology
|
|
3-Amino-3-phenylpropionic acid (DL-β-Phenylalanine) is a structural GABA analogue. 3-Amino-3-phenylpropionic acid inhibits baclofen (HY-B0007) induced gastric acid secretion .
|
-
- HY-17623S
-
|
CJ-12420-d6; RQ-00000004-d6
|
Proton Pump
Na+/K+ ATPase
|
Metabolic Disease
|
|
Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
|
-
- HY-B0377S
-
-
- HY-B0281A
-
-
- HY-17037
-
|
LS 519; Pirenzepin dihydrochloride; Gastrozepin dihydrochloride
|
mAChR
|
Metabolic Disease
Cancer
|
|
Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
|
-
- HY-P1070A
-
|
DAP amide, human TFA
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .
|
-
- HY-B0693
-
-
- HY-17021C
-
|
(S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium
|
Proton Pump
Bacterial
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .
|
-
- HY-W008614R
-
|
|
Drug Metabolite
Proton Pump
|
Metabolic Disease
|
|
Lansoprazole sulfone (Standard) is the analytical standard of Lansoprazole sulfone. This product is intended for research and analytical applications. Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H+, K+-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H+, K+-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
|
-
- HY-B0310
-
-
- HY-17021A
-
|
(S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt
|
Proton Pump
Bacterial
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .
|
-
- HY-P2541
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
|
-
- HY-17037A
-
|
LS 519 free base; Pirenzepin; Gastrozepin
|
mAChR
|
Metabolic Disease
Cancer
|
|
Pirenzepine (LS 519 free base) is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine shows anti-proliferative activity to cancer cells .
|
-
- HY-W707517
-
-
- HY-129923R
-
|
|
HBV
|
Neurological Disease
|
|
(R)-Omeprazole (sodium) (Standard) is the analytical standard of (R)-Omeprazole (sodium). This product is intended for research and analytical applications. (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19 .
|
-
- HY-134338R
-
|
|
Parasite
|
Others
|
|
(R)-Omeprazole (sodium) (Standard) is the analytical standard of (R)-Omeprazole (sodium). This product is intended for research and analytical applications. (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19 .
|
-
- HY-P2541A
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
|
-
- HY-100413
-
|
|
Proton Pump
|
Inflammation/Immunology
|
|
CS-526 is a potent, selective, reversible and orally active acid pump antagonist. CS-526 inhibits H +,K +-ATPase activity. CS-526 inhibits gastric acid secretion and prevents esophageal lesions. CS-526 has the potential for the research of gastroesophageal reflux disease .
|
-
- HY-103545
-
|
gastric inhibitory peptide (1-39) (porcine)
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca 2+ concentration ([Ca 2+]i), and capable of enhancing exocytosis .
|
-
- HY-17023S
-
|
(S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium
|
Isotope-Labeled Compounds
Proton Pump
|
Others
|
|
Esomeprazole-d6 sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
|
-
- HY-120381
-
|
CAM 1189
|
Cholecystokinin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC50=1 mg/kg), and ameliorates the haemorrhagic lesions (IC50=4.7 mg/kg) in rats .
|
-
- HY-W008614S
-
|
AG-1813-d4
|
Isotope-Labeled Compounds
Proton Pump
|
Others
|
|
Lansoprazole sulfone-d4 (AG-1813-d4) is the deuterium labeled Lansoprazole sulfone. Lansoprazole sulfone-d4 is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone-d4 can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone-d4 has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
|
-
- HY-17021S
-
|
(S)-Omeprazole-d3 sodium; (-)-Omeprazole-d3 sodium
|
Isotope-Labeled Compounds
Proton Pump
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Esomeprazole-d3 (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
|
-
- HY-17021S1
-
|
(S)-Omeprazole-d3; (-)-Omeprazole-d3
|
Isotope-Labeled Compounds
Proton Pump
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Esomeprazole-d3 is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
|
-
- HY-B1330
-
|
|
Cholecystokinin Receptor
|
Neurological Disease
Endocrinology
Cancer
|
|
Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
|
-
- HY-103354
-
|
|
Cholecystokinin Receptor
|
Neurological Disease
Endocrinology
Cancer
|
|
Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
|
-
- HY-100481
-
|
RPR101048
|
Cholecystokinin Receptor
|
Neurological Disease
|
|
RP 72540 is a selective CCK-B receptor antagonist, with IC50 values of 2.4, 1.2, and 3.8 nM for CCK-B receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits CCK-8-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors .
|
-
- HY-B0310S
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Nizatidine-d3 is the deuterium labeled Nizatidine. Nizatidine is a potent and orally active histamine H2 receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models[1].
|
-
- HY-103355
-
YM022
2 Publications Verification
|
CCR
|
Metabolic Disease
|
|
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .
|
-
- HY-145578
-
|
X842
|
Drug Intermediate
|
Inflammation/Immunology
|
|
Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1) .
|
-
- HY-17021S2
-
|
(S)-Omeprazole-d3 potassium; (-)-Omeprazole-d3 potassium
|
Bacterial
Proton Pump
Isotope-Labeled Compounds
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Esomeprazole-d3 potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
|
-
- HY-17021R
-
|
|
Proton Pump
Bacterial
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Esomeprazole (Standard) is the analytical standard of Esomeprazole. This product is intended for research and analytical applications. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
|
-
- HY-B0281AS
-
-
- HY-103354A
-
|
|
Cholecystokinin Receptor
|
Neurological Disease
Endocrinology
Cancer
|
|
Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities .
|
-
- HY-B0281AR
-
|
|
Histamine Receptor
Cytochrome P450
Bacterial
|
Infection
Metabolic Disease
Endocrinology
Cancer
|
|
Ranitidine (hydrochloride) (Standard) is the analytical standard of Ranitidine (hydrochloride). This product is intended for research and analytical applications. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of CYP2C19 and CYP2C9 .
|
-
- HY-B0310R
-
|
|
Histamine Receptor
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Nizatidine (Standard) is the analytical standard of Nizatidine. This product is intended for research and analytical applications. Nizatidine is a potent and orally active histamine H2 receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models .
|
-
- HY-17037R
-
|
|
mAChR
|
Metabolic Disease
Cancer
|
|
Pirenzepine (dihydrochloride) (Standard) is the analytical standard of Pirenzepine (dihydrochloride). This product is intended for research and analytical applications. Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
|
-
- HY-17023
-
|
(S)-Omeprazole sodium; (-)-Omeprazole sodium
|
Proton Pump
Bacterial
|
Endocrinology
Cancer
|
|
Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
|
-
- HY-W011245R
-
|
|
Drug Metabolite
|
Metabolic Disease
|
|
Ranitidine S-oxide (Standard) is the analytical standard of Ranitidine S-oxide. This product is intended for research and analytical applications. Ranitidine S-oxide is the metabolite of Ranitidine (HY-B0693). Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion .
|
-
- HY-137941
-
|
|
Histamine Receptor
Caspase
NF-κB
p38 MAPK
|
Inflammation/Immunology
|
|
Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is an orally active histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect. Roxatidine is promising for research of gastric and duodenal ulcers .
|
-
- HY-130522
-
|
6β-PGI1
|
Prostaglandin Receptor
|
Others
|
|
6β-Prostaglandin I1 (6β-PGI1) is an analog of prostaglandin I2 (PGI2) that is resistant to hydrolysis in aqueous solutions. 6β-Prostaglandin I1 can reduce gastric acid secretion with an ID50 (dose causing 50% inhibition) of approximately 3.0 μg/kg/min (intravenous injection) .
|
-
- HY-100414
-
|
BYK61359
|
Proton Pump
|
Metabolic Disease
|
|
Soraprazan (BYK61359) is a selective, reversible K-competitive inhibitor of the H,K-ATPase (Ki=6.4 nM), with an IC50 of 0.19 μM in gastric glands. Soraprazan binds to the H,K-ATPase with a Kd of 28.27 nM. Soraprazan shows immediate inhibition of acid secretion and is more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases .
|
-
- HY-103377
-
|
|
CRFR
|
Inflammation/Immunology
Endocrinology
|
|
Antalarmin (hydrochloride) is an oral active non-peptide corticotropin-releasing hormone receptor 1 (CRHR1) antagonist with a Ki of 1 nM. Antalarmin hydrochloride suppresses CRH-induced ACTH secretion and blocks CRH and novelty induced anxiety-like behavior in animal models. Antalarmin hydrochloride produces anti-inflammatory effects in arthritis models, and suppresses stress-induced gastric ulceration related to irritable bowel syndrome .
|
-
- HY-111313
-
|
|
Cholecystokinin Receptor
|
Metabolic Disease
|
|
JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .
|
-
- HY-17037S1
-
|
LS 519-d8 dihydrochloride; Pirenzepin-d8 dihydrochloride; Gastrozepin-d8 dihydrochloride
|
Isotope-Labeled Compounds
mAChR
|
Cancer
|
|
Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
|
-
- HY-17023R
-
|
(S)-Omeprazole (sodium) (Standard); (-)-Omeprazole (sodium) (Standard)
|
Proton Pump
Bacterial
|
Endocrinology
Cancer
|
|
Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
|
-
- HY-124517
-
|
|
Histamine Receptor
Adrenergic Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Burimamide is a blocker of histamine H2-receptor. Burimamide inhibits gastric acid secretion evoked by Pentagastrin (HY-A0261) or Gastrin. Burimamide also has alpha-adrenoceptor blocking activity. Burimamide in combination with the H1-receptor antagonist Mepyramine (HY-B1281) shows anti-inflammatory activity in a rat paw edema model induced by Compound 48/80 (HY-115768) .
|
-
- HY-118665
-
|
|
Cholecystokinin Receptor
|
Metabolic Disease
|
|
L-736380 is a high affinity CCK-B (cholecystokinin B receptor) receptor antagonist, with IC50 values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID50, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED50, 1.7 mg/kg) .
|
-
- HY-100958
-
4-DAMP
3 Publications Verification
4-DAMP methiodide
|
mAChR
Apoptosis
MMP
EGFR
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
4-DAMP (4-DAMP methiodide) is a potent and selective antagonist of M3 receptors and also has a high affinity for the closely-related M5 receptors. 4-DAMP combined with 5-Fluorouracil (5-Fu) (HY-90006) could significantly reduce the cell viability and enhance apoptosis in MKN45 and BGC823 gastric cancer cells. 4-DAMP inhibits lipopolysaccharide (LPS)- and tobacco-induced pulmonary inflammation and reduces mucin 5AC (MUC5AC), oligomeric mucus/gel-forming secretion .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-B0377G
-
|
MK-208 (GMP)
|
Fluorescent Dye
|
|
Famotidine GMP (MK-208 GMP) is Famotidine (HY-B0377) produced in GMP guideline. Famotidine GMP is a competitive histamine H2-receptor antagonist, inhibits gastric secretion, activates the gastric mucosal defensive mechanisms. Famotidine GMP ameliorates peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) in rats model .
|
| Cat. No. |
Product Name |
Type |
-
- HY-W002039
-
|
DL-β-Phenylalanine
|
Biochemical Assay Reagents
|
|
3-Amino-3-phenylpropionic acid (DL-β-Phenylalanine) is a structural GABA analogue. 3-Amino-3-phenylpropionic acid inhibits baclofen (HY-B0007) induced gastric acid secretion .
|
-
- HY-B0377G
-
|
MK-208 (GMP)
|
Biochemical Assay Reagents
|
|
Famotidine GMP (MK-208 GMP) is Famotidine (HY-B0377) produced in GMP guideline. Famotidine GMP is a competitive histamine H2-receptor antagonist, inhibits gastric secretion, activates the gastric mucosal defensive mechanisms. Famotidine GMP ameliorates peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) in rats model .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P2416
-
-
- HY-125556
-
|
Cholecystokinin tetrapeptide; CCK-4
|
Cholecystokinin Receptor
|
Metabolic Disease
|
|
Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion . Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist . Gastric mucosal protection .
|
-
- HY-P0253
-
-
- HY-P1097
-
-
- HY-P0276
-
|
gastric Inhibitory Peptide (GIP), human
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
|
-
- HY-P0276A
-
|
gastric Inhibitory Peptide (GIP), human TFA
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
|
-
- HY-P1139
-
|
PCFWKTCK
|
GHSR
|
Metabolic Disease
|
|
Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .
|
-
- HY-P3577
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .
|
-
- HY-P1784
-
|
|
Secretin Receptor
|
Endocrinology
|
|
Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway .
|
-
- HY-P0253A
-
|
|
Neurotensin Receptor
|
Metabolic Disease
|
|
Xenopsin TFA, a neurotensin-like octapeptide from Xenopus laevis skin . Xenopsin TFA is an inhibitor of Tetragastrin stimulated gastric acid secretion .
|
-
- HY-103281
-
|
|
Bombesin Receptor
|
Metabolic Disease
|
|
Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .
|
-
- HY-P1806
-
|
|
Peptides
|
Metabolic Disease
Endocrinology
|
|
Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion .
|
-
- HY-P1806A
-
-
- HY-103276
-
-
- HY-P1070
-
|
DAP amide, human
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .
|
-
- HY-P1070A
-
|
DAP amide, human TFA
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .
|
-
- HY-P2541
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
|
-
- HY-P2541A
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
|
-
- HY-103545
-
|
gastric inhibitory peptide (1-39) (porcine)
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca 2+ concentration ([Ca 2+]i), and capable of enhancing exocytosis .
|
-
- HY-P5390
-
|
|
Peptides
|
Others
|
|
GIP, rat is a biological active peptide. (GIP (Glucose-dependent Insulinotropic Polypeptide or also known as Gastric Inhibitory Polypeptide) is a 42-amino acid peptide released by the K cells of the duodenum and jejunum in response to food intake. GIP, together with GLP (Gastric-like Peptide) are members of the hormone peptide family of Incretins which stimulate insulin secretion from pancreatic islet β-cells, and also appears to promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and possibly in the pathogenesis of obesity.)
|
-
- HY-P5390A
-
|
|
Peptides
|
Others
|
|
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0310S
-
|
|
|
Nizatidine-d3 is the deuterium labeled Nizatidine. Nizatidine is a potent and orally active histamine H2 receptor antagonist, can be used for the research of stomach and intestines ulcers. Nizatidine works by decreasing the secretion of gastric acid the stomach makes and prevent ulcers from coming back after they have healed in animal models[1].
|
-
-
- HY-B0281AS
-
|
|
|
Ranitidine-d6 (hydrochloride) is the deuterium labeled Ranitidine hydrochloride. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of CYP2C19 and CYP2C9[1][2].
|
-
-
- HY-17623S
-
|
|
|
Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
|
-
-
- HY-B0377S
-
|
|
|
Famotidine- 13C,d3 is the 13C- and deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
|
-
-
- HY-W707517
-
|
|
|
Famotidine-d4 (MK-208-d4) is deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion .
|
-
-
- HY-17023S
-
|
|
|
Esomeprazole-d6 sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
|
-
-
- HY-W008614S
-
|
|
|
Lansoprazole sulfone-d4 (AG-1813-d4) is the deuterium labeled Lansoprazole sulfone. Lansoprazole sulfone-d4 is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone-d4 can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone-d4 has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
|
-
-
- HY-17021S
-
|
|
|
Esomeprazole-d3 (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
|
-
-
- HY-17021S1
-
|
|
|
Esomeprazole-d3 is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
|
-
-
- HY-17021S2
-
|
|
|
Esomeprazole-d3 potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
|
-
-
- HY-17037S1
-
|
|
|
Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![[Tyr0] Gastric Inhibitory Peptide (23-42), human](http://file.medchemexpress.eu/product_pic/hy-p3577.gif)
